These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37468890)

  • 1. Exploring the relationship between North Star Ambulatory Assessment and Health Utilities Index scores in Duchenne muscular dystrophy.
    Audhya I; Rogula B; Szabo SM; Feeny D; Bolatova T; Gooch K
    Health Qual Life Outcomes; 2023 Jul; 21(1):76. PubMed ID: 37468890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI).
    Szabo SM; Audhya IF; Rogula B; Feeny D; Gooch KL
    Health Qual Life Outcomes; 2022 Jun; 20(1):93. PubMed ID: 35690783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L.
    Audhya IF; Szabo SM; Bever A; O'Sullivan F; Malone DC; Feeny D; Neumann P; Iannaccone ST; Jayasinghe P; Gooch KL
    J Patient Rep Outcomes; 2023 Dec; 7(1):132. PubMed ID: 38100005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.
    Neumann PJ; Sandberg EA; Araki SS; Kuntz KM; Feeny D; Weinstein MC
    Med Decis Making; 2000; 20(4):413-22. PubMed ID: 11059474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of motor proficiency and functional ambulation in Duchenne muscular dystrophy with healthy peers.
    Yildiz S; Sahin S; Bulut N; Tunca Yilmaz O; Karaduman AA; Akel BS
    Somatosens Mot Res; 2020 Dec; 37(4):252-256. PubMed ID: 32583706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
    Ayyar Gupta V; Pitchforth JM; Domingos J; Ridout D; Iodice M; Rye C; Chesshyre M; Wolfe A; Selby V; Mayhew A; Mazzone ES; Ricotti V; Hogrel JY; Niks EH; de Groot I; Servais L; Straub V; Mercuri E; Manzur AY; Muntoni F;
    PLoS One; 2023; 18(4):e0283669. PubMed ID: 37099511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons.
    Feeny D; Furlong W; Saigal S; Sun J
    Soc Sci Med; 2004 Feb; 58(4):799-809. PubMed ID: 14672594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to analysis of the North Star Ambulatory Assessment (NSAA) in Duchenne muscular dystrophy (DMD): Observations from a phase 2 trial.
    Muntoni F; Guglieri M; Mah JK; Wagner KR; Brandsema JF; Butterfield RJ; McDonald CM; Mayhew AG; Palmer JP; Marraffino S; Charnas L; Mercuri E
    PLoS One; 2022; 17(8):e0272858. PubMed ID: 35998119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutual concurrent validity of the child health questionnaire and the health utilities index: an exploratory analysis using survivors of childhood cancer.
    Nixon Speechley K; Maunsell E; Desmeules M; Schanzer D; Landgraf JM; Feeny DH; Barrera ME
    Int J Cancer Suppl; 1999; 12():95-105. PubMed ID: 10679879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma.
    Ungar WJ; Boydell K; Dell S; Feldman BM; Marshall D; Willan A; Wright JG
    Pharmacoeconomics; 2012 Aug; 30(8):697-712. PubMed ID: 22788260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness and construct validity of the health utilities index in patients with dementia.
    Kavirajan H; Hays RD; Vassar S; Vickrey BG
    Med Care; 2009 Jun; 47(6):651-61. PubMed ID: 19433998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew AG; Cano SJ; Scott E; Eagle M; Bushby K; Manzur A; Muntoni F;
    Dev Med Child Neurol; 2013 Nov; 55(11):1046-52. PubMed ID: 23909763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.
    Raisch DW; Feeney P; Goff DC; Narayan KM; O'Connor PJ; Zhang P; Hire DG; Sullivan MD
    Cardiovasc Diabetol; 2012 Jul; 11():35. PubMed ID: 22515638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construct validity for the Health Utilities Index in a sleep center.
    Welch KC; Scharf SM
    Sleep Breath; 2007 Dec; 11(4):295-303. PubMed ID: 17457630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.
    Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP
    Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.